Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-05-24
2011-05-24
Qazi, Sabiha (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S177000, C552S558000
Reexamination Certificate
active
07947667
ABSTRACT:
A process for preparing an intermediate compound of formula (II)where X is as defined in the specification, R1is haloalkyl, alkyl, alkenyl, cycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl or arylalkyl;R2, R3, R4and R5are organic groups as defined in the specification, which process comprises aromatisation of a compound of formula (III)where R1, R2, R3, n, X and R5are as defined in relation to formula (II) and R4′is a group R4or a precursor group thereof, and thereafter if necessary or desired, carrying out one or more of the following steps: (i) removing any hydroxy-protecting groups R; (ii) converting a precursor group R4′to a group R4, or where R4′is a group R4, converting it to a different such group.Compounds obtained are useful intermediates for example in the preparation of fulvestrant. Novel intermediates are also claimed.
REFERENCES:
patent: 3944576 (1976-03-01), van den Broek et al.
patent: 4659516 (1987-04-01), Bowler et al.
patent: 5211831 (1993-05-01), Vitale et al.
patent: 5502046 (1996-03-01), Bohlmann et al.
patent: 5595985 (1997-01-01), Labrie
patent: 5952319 (1999-09-01), Cook et al.
patent: 6288051 (2001-09-01), Bittler et al.
patent: 7196074 (2007-03-01), Blye et al.
patent: 7323602 (2008-01-01), Warren et al.
patent: 0 138 504 (1985-04-01), None
patent: 93/06124 (1993-04-01), None
Bowler, J., et al., “Novel Steroidal Pure Antiestrogens,” Steroids, 54(1):71-99 (1989).
Golob, T., et al., “Antiestrogenic Activities of 3,8-Dihydroxy-6,11-dihydrobenzo[a]carbazoles with Sulfur-Containing Side Chains,” Arch. Pharm. Pharm. Med. Chem., 333:305-311 (2000).
Bowler, Jean et al., Novel Steroidal Pure Antiestrogens, Steroids, Jul. 1989, pp. 71-99, vol. 54/1.
Modi, Sandeep P. et al., Conjugate Addition of Grignard Reagants to Enones and Dienones, 1989, pp. 2317-2321, vol. 54.
Rao, Pemmaraju, N., et al., Preparative Chemical Methods for aromatization of 19-nor-delta4-3-oxosteroids, Steroids, Nov. 1994, pp. 621-627, vol. 59.
Wakeling AE, et al. Therapeutic Potential of Pure Antioestrogens in the Treatment of Breast Cancer, Steroid Biochemistry, 1990c, vol. 37, pp. 771-775.
Wakeling AE, et al., Steroidal Pure Antioestrogen, J. Endocrinology 1987, vol. 112: pp. R7-R10.
Wakeling AE, et al., Biology and Mode of Action of Pure Antioestrogens, J. Steroid Biochemistry, 1988, vol. 30 No. 1-6, 141-147.
Howell et al., Response to a specific antioestrogen (ICI 182780) in tarmoxifen-resistant breast cancer, The Lancet, Jan. 7, 1995, vol. 345, pp. 29-30.
Brazier Eve Joanne
Hogan Phillip John
Kerr Fraser Witton
Laffan David Dermot Patrick
Lane Anthony Raymond
Astrazeneca AB
Qazi Sabiha
LandOfFree
Process and intermediates for the production of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process and intermediates for the production of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process and intermediates for the production of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704364